300 NORTH CAPITAL, LLC - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 183 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2014. The put-call ratio across all filers is 1.68 and the average weighting 0.1%.

Quarter-by-quarter ownership
300 NORTH CAPITAL, LLC ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q1 2015$736,000
+81.7%
2,609
+0.5%
0.16%
+74.2%
Q4 2014$405,000
-33.8%
2,595
+0.3%
0.09%
-42.6%
Q3 2014$612,0000.0%2,5880.0%0.16%
+7.3%
Q2 2014$612,000
-28.3%
2,5880.0%0.15%
-31.7%
Q1 2014$854,0002,5880.22%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q3 2014
NameSharesValueWeighting ↓
Samsara BioCapital, LLC 234,375$23,623,00022.67%
Boxer Capital, LLC 600,000$60,474,0007.47%
DLD Asset Management, LP 834,600$84,136,0005.77%
GREAT POINT PARTNERS LLC 200,000$20,158,0002.55%
BB BIOTECH AG 575,719$58,027,0001.86%
Elk Creek Partners, LLC 207,657$20,930,0001.74%
ALTRINSIC GLOBAL ADVISORS LLC 277,944$28,014,0001.34%
Sarissa Capital Management LP 54,000$5,442,0001.21%
QCM Cayman, Ltd. 2,181$220,0000.90%
Opus Point Partners Management, LLC 3,534$356,0000.78%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders